Guardant Health, ConcertAI team for RWD that integrates EMR data for cancer care

Guardant Health (GH) announced a collaboration agreement that allows biopharmaceutical companies to access the first multi-modal real-world data RWD that integrates comprehensive patient electronic medical record EMR data with both genomic and epigenomic tumor profiling information across the continuum of cancer care. An individual patient’s cancer is complex, with response to medicines being determined by multiple factors, including specific driver mutations from the cancer, previous therapies and acquired resistance to those therapies. The creation of a joint RWD solution provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. This allows biopharma collaborators to better interpret disease biology and identify drivers and timing of tumor evolution as well as intrinsic and acquired resistance mechanisms. These are critical insights with causal associations that can guide the design of clinical trials and effective therapeutics. Through this collaboration, biopharmaceutical company partners can now leverage the joint dataset, combined analytics capability, AI SaaS solutions and precision oncology footprint of ConcertAI and Guardant Health.